108 related articles for article (PubMed ID: 2089202)
1. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
[TBL] [Abstract][Full Text] [Related]
2. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
3. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients.
Wirtz JJ; van Esser JW; Hamulyák K; Leunissen KM; van Hooff JP
Clin Nephrol; 1992 Nov; 38(5):277-82. PubMed ID: 1451341
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
5. [Hemostatic changes associated with recombinant human erythropoietin (rHu Epo) treatment].
Vinhas J; Assis P; Oliveira C; Crespo F; Prata MM
Acta Med Port; 1991; 4(1):9-12. PubMed ID: 2048426
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA
Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
[TBL] [Abstract][Full Text] [Related]
7. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
10. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
[TBL] [Abstract][Full Text] [Related]
11. [Effect of erythropoietin therapy on alpha receptor density in chronic dialysis patients].
Fritschka E; Neumayer HH; Seddighi S; Distler A; Philipp T
Med Klin (Munich); 1991 Jul; 86(7):353-9. PubMed ID: 1656181
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin treatment improves platelet function in uremic patients.
Cases A; Escolar G; Reverter JC; Ordinas A; Lopez-Pedret J; Revert L; Castillo R
Kidney Int; 1992 Sep; 42(3):668-72. PubMed ID: 1405344
[TBL] [Abstract][Full Text] [Related]
13. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
[TBL] [Abstract][Full Text] [Related]
14. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
[TBL] [Abstract][Full Text] [Related]
15. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
17. Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies.
Borawski J; Rydzewski A; Azzadin A; Buczko W; Mysliwiec M
Platelets; 1998; 9(1):31-5. PubMed ID: 16793742
[TBL] [Abstract][Full Text] [Related]
18. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
[TBL] [Abstract][Full Text] [Related]
19. The effect of recombinant human erythropoietin (r-Hu EPO) administration on the blood chemistries and composition in uremic rats.
Kozioł M; Ksiazek P; Feldo M; Spasiewicz D; Michalak J; Kleinrok Z
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():61-6. PubMed ID: 8192533
[TBL] [Abstract][Full Text] [Related]
20. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]